Ob/Gyn Medical News about vaginal atrophy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy
Expert Opinion in Pharmacotherapy, 08/14/09

Gennari L – In postmenopausal women with osteoporosis, lasofoxifene treatment also reduced ER positive breast cancer risk and the occurrence of vaginal atrophy. With its increased potency and efficacy on the prevention of nonvertebral fractures and its positive effects on the vagina, this new SERM may represent an alternative therapy for osteoporosis in postmenopausal women.

<< Previous
Severe hypoglycaemia during pregnancy in women with Type 1...

Next >>
Secondary Cytoreduction in Epithelial Ovarian Cancer Recurrence:...